Lifitegrast Shows Long-Term Safety and Efficacy for Dry Eye Disease in 7-Year Analysis
• A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.
• Real-world assessment data presented at the 2025 ASCRS Annual Meeting shows approximately two-thirds of patients achieved near or complete symptom resolution after 1-3 months of lifitegrast treatment.
• Lifitegrast demonstrates sustained efficacy for dry eye disease management, with particular utility in contact lens wearers and patients undergoing various ocular surgeries.
MIEBO Demonstrates Efficacy in Dry Eye Disease Treatment
• MIEBO (perfluorohexyloctane ophthalmic solution) is FDA-approved for treating the signs and symptoms of dry eye disease (DED).
• Clinical trials (GOBI and MOJAVE) involving 1,217 patients showed MIEBO significantly improved corneal smoothness and reduced eye dryness symptoms after 57 days.
• The most common side effects reported in the trials were blurred vision and conjunctival redness, each affecting 1% to 3% of patients.
• Subgroup analyses indicated MIEBO's efficacy and safety were consistent across different sex, race, and age groups.
R3 Vascular Secures $87 Million in Series B Financing and Appoints New CEO
R3 Vascular Inc., a medical device company focused on developing bioresorbable scaffolds for peripheral arterial disease (PAD), has announced the completion of an $87 million Series B financing round. The funding, led by Deerfield Management, will support the ELITE FDA IDE pivotal trial of its MAGNITUDE® bioresorbable scaffold for below-the-knee PAD, alongside R&D, regulatory submissions, and manufacturing scale-up. Christopher M. Owens has been appointed as the new President and CEO, bringing over three decades of medical device industry experience to the role.
© Copyright 2025. All Rights Reserved by MedPath